Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)

Craig C. Hofmeister,Paul G. Richardson,Todd M. Zimmerman,Matthew A. Spear,Michael A. Palladino,Angie M. Longenecker,Gillian F. Cropp,G. K. Lloyd,Alison L. Hannah,Kc Anderson

Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)

2009

Craig C. Hofmeister
Paul G. Richardson
Todd M. Zimmerman
Matthew A. Spear
Michael A. Palladino
Angie M. Longenecker
Gillian F. Cropp
G. K. Lloyd
Alison L. Hannah
Kc Anderson

8505 Background: NPI-0052 produces rapid, broad and prolonged inhibition of all 3 catalytic activities of the 20S proteasome. NPI-0052 has a non-peptide based structure that appears to result in a ...

Keywords:

Oncology
Refractory Multiple Myeloma
Clinical trial
Internal medicine
Proteasome inhibitor NPI-0052
Medicine
20s proteasome
Pathology
relapsed refractory
Multiple myeloma
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations